Mostrando 10 resultados de: 16
Filtros aplicados
Publisher
Cell and Bioscience(2)
Cancers(1)
Colloids and Surfaces B: Biointerfaces(1)
Current Neuropharmacology(1)
Expert Opinion on Drug Discovery(1)
Área temáticas
Farmacología y terapéutica(14)
Enfermedades(11)
Medicina y salud(8)
Fisiología humana(4)
Bioquímica(1)
Área de conocimiento
Biomedicina(3)
Nanopartícula(3)
Neurología(3)
Biotecnología(2)
Descubrimiento de fármacos(2)
Origen
scopus(16)
A novel rhein-huprine hybrid ameliorates disease-modifying properties in preclinical mice model of Alzheimer’s disease exacerbated with high fat diet
ArticleAbstract: Background: Alzheimer’s disease (AD) is characterized by a polyetiological origin. Despite the globaPalabras claves:Alzheimer’s disease, BACE1, BDNF, cognitive decline, dendritic spines, high-fat diet, neuroinflammation, Rhein-huprine hybrid, Tau, TLR4Autores:Antoni Camins, Auladell C., Bulló M., Cano A., Espinosa-Jimenez T., Ettcheto M., Folch J., Muñoz-Torrero D., Olloquequi J., Parcerisas A., Pont C., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusDevelopment and optimization of Riluzole-loaded biodegradable nanoparticles incorporated in a mucoadhesive in situ gel for the posterior eye segment
ArticleAbstract: Riluzole-loaded PLGA nanoparticles (RLZ-NPs) were developed to improve the biopharmaceutical profilePalabras claves:Gellan gum, glaucoma, In situ gelling gel, PLGA nanoparticles, riluzoleAutores:Antoni Camins, Cano A., Espina M., Esteruelas G., Ettcheto M., García-Torra V., Halbaut L., Luisa García M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusDevelopment of Peptide Targeted PLGA-PEGylated Nanoparticles Loading Licochalcone-A for Ocular Inflammation
ArticleAbstract: Licochalcone-A is a natural compound with anti-inflammatory properties. However, it possesses low waPalabras claves:cell-penetrating peptides, Licochalcone-A, Nanoparticles, Ocular inflammation, PLGAAutores:Antoni Camins, Cano A., Espina M., Ettcheto M., Galindo R., García M.L., Gómara M.J., Haro I., Sanchez-Lopez E.Fuentes:scopusDexibuprofen ameliorates peripheral and central risk factors associated with Alzheimer’s disease in metabolically stressed APPswe/PS1dE9 mice
ArticleAbstract: Background: Several studies stablished a relationship between metabolic disturbances and Alzheimer´sPalabras claves:Alzheimer´s disease, APPswe/PS1dE9, Cognitive deficits, Dexibuprofen, High fat diet, Metabolic alterations, neuroinflammation, synapsis, unfolded protein response, βA plaquesAutores:Antoni Camins, Auladell C., Busquets O., Cano A., Carrasco M., Espinosa-Jimenez T., Ettcheto M., Folch J., Herrera K., Manzine P.R., Olloquequi J., Sanchez-Lopez E., Verdaguer E.Fuentes:scopusArticle dexibuprofen biodegradable nanoparticles: One step closer towards a better ocular interaction study
ArticleAbstract: Ocular inflammation is one of the most prevalent diseases in ophthalmology, which can affect variousPalabras claves:Dexibuprofen, Drug delivery system, Nanoparticles, PLGAAutores:Alsafi Z., Antoni Camins, Calpena A.C., Cano A., Espina M., Esteruelas G., Ettcheto M., García M.L., Muñoz M., Ortiz A., Prat J., Pujol M., Sanchez-Lopez E., Souto E.M.B.Fuentes:scopusEpigallocatechin-3-gallate loaded PEGylated-PLGA nanoparticles: A new anti-seizure strategy for temporal lobe epilepsy
ArticleAbstract: Temporal lobe epilepsy is the most common type of pharmacoresistant epilepsy in adults. EpigallocatePalabras claves:Epigallocatechin-3-gallate, Epilepsy, PLGA-PEG, Polymeric nanoparticlesAutores:Antoni Camins, Auladell C., Barenys M., Calpena A.C., Cano A., Espina M., Ettcheto M., Folch J., García M.L., Sanchez-Lopez E.Fuentes:scopusExperimental models for aging and their potential for novel drug discovery
ReviewAbstract: Background: An interesting area of scientific research is the development of potential antiaging druPalabras claves:aging, Heterogeneous mice model, IGF-1, mTOR, Resveratrol, SAMP8, SirtuinsAutores:Antoni Camins, Auladell C., Busquets O., Casadesús G., Ettcheto M., Folch J., Miguel Marin, Olloquequi J., Pallás M., Sanchez-Lopez E., Zárate C.B.Fuentes:scopusDiscovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice
ArticleAbstract: The combination of the scaffolds of the cholinesterase inhibitor huprine Y and the antioxidant capsaPalabras claves:Autores:Andrisano V., Antoni Camins, Bartolini M., Brazzolotto X., Cieslikiewicz-Bouet M., Cisternas P., Colletier J.P., Coquelle N., De Simone A., Ettcheto M., Firuzi O., García M.L., Inestrosa N.C., Jean L., Muñoz-Torrero D., Nachon F., Oliva C.A., Perez B., Pons M., Renard P.Y., Rendina M., Ricchini M., Sanchez-Lopez E., Saso L., Silman I., Viayna E.Fuentes:scopusPEGylated PLGA nanospheres optimized by design of experiments for ocular administration of dexibuprofen-in vitro, ex vivo and in vivo characterization
ArticleAbstract: Dexibuprofen-loaded PEGylated PLGA nanospheres have been developed to improve the biopharmaceuticalPalabras claves:Dexibuprofen, drug delivery, inflammation, Nanospheres, PEG, PLGAAutores:Antoni Camins, Calpena A.C., Cano A., Egea M.A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Silva A.M., Souto E.M.B.Fuentes:scopusMemantine loaded PLGA PEGylated nanoparticles for Alzheimer's disease: In vitro and in vivo characterization
ArticleAbstract: Background: Memantine, drug approved for moderate to severe Alzheimer's disease, has not shown to bePalabras claves:Alzheimer's disease, APPswe/PS1dE9 mice, astrocytes, BEnd.3, Brain targeting, Memantine, Nanoparticles, β-Amyloid plaquesAutores:Antoni Camins, Calpena A.C., Cano A., Carmona N., Egea M.A., Espina M., Ettcheto M., García M.L., Sanchez-Lopez E., Silva A.M., Souto E.M.B.Fuentes:scopus